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ABSTRACT 
The plan behind the present research work was to develop a microsponge based dosage form for modified delivery of voriconazole prepared by 
quasi-emulsion solvent diffusion method using polymer Ethylcellulose with two factors drug-polymer ratios and surfactant concentration, 
these two factors influences micro particles and physical properties. The characterization techniques followed for the formed microsponges 
were DSC, FT-IR, SEM and particle size analysis, along with morphology, drug loading, in-vitro drug release data.  DSC and FT-IR data discloses 
that there were no chemical interactions between drug and polymer used. The drug-polymer ratio and surfactant concentration showed 
notable impact on drug content, encapsulation efficiency and particle size, SEM micrographs revealed that microsponges formed were spherical 
in shape with porous surface, and had 119.47 μm mean particle size. The microsponges were then loaded in carbopol gel followed by ex vivo 
drug deposition, primary skin irritancy study, in vivo antibacterial activity and in-vitro drug release study; which depicted that microsponges 
with drug-polymer ratio of 1:3 were more capable to give extended drug release of 93.79.±0.06 % at the end of 24 h, better in contrast to 
conventional formulation. Hence, the developed microsponge based formulation of voriconazole would be a hopeful, promising alternate to 
conventional therapy for the fungal treatment. 
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INTRODUCTION 
Drug delivery through skin is a powerful technique for local 
as well as systemic administration of biological response 
modifiers. The topical administration evades gastric 
irritation and hepatic first pass metabolism evident from oral 
treatment. The topical delivery recommends a sustained 
release of drug at the site of application as well as 
termination of therapy by removal of the formulation in case 
where toxic effects are noticed. 
The barrier function of skin in transdermal drug delivery is 
due to the outermost layer of the skin, the stratum corneum 
encompass a vascular dead keratinized cells1. As a result, 
diverse methodologies are adapted to achieve desired 
therapeutic activity from a topical formulation. One such 
methodology is microsponge-based delivery systems (MDS) 
Voriconazole is a low molecular weight synthetic triazole 
antifungal drug for the treatment of superficial and systemic 
fungal infections. Voriconazole has confirmed activity against 
aspergillosis, candida infections, scedosporium 
apiospermum and fusarium spp., the oral and parenteral 
administration of voriconazole repeatedly produces injection 
site reactions and allergic reactions. The oral administration 
of voriconazole is reported to interact with a number of 
medicines, which include rifampicin, rifabutin, 
carbamazepine, quinidine and ergot alkaloids2-4. These 
issues might be overwhelmed by adopting novel approach of 
voriconazole. 
MDS gives guarantee of drug localization on skin surface and 
inside epidermis without entering in systemic circulation in 
greater extent; in this manner decreasing systemic and local 
cutaneous adverse effects. MDS likewise recommend 
preference of programmable release and are biologically 
protected. In addition, this innovation shows moderately a 
lot of benefits via drug entrapment by means of better 
formulation flexibility, reduced side effects, improved 
elegance and better stability5-8. 
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Thus, taking into consideration the benefits of MDS, the 
objective of this current investigation was aspired to 
formulate and evaluate voriconazole microsponge loaded 
carbopol gel for its promising effects over extended period of 
time. 
MATERIAL AND METHODS 
Materials 
Voriconazole, ethyl cellulose 50 cps, polyvinyl alcohol, 
carbopol 934 triethanolamine, disodium hydrogen 
phosphate, potassium dihydrogen phosphate, triethyl citrate 
and ethyl acetate were used. 
Methodology 
Preformulation studies 
 (a) Drug – Excipients compatibility studies by DSC  
DSC studies were carried out using Mettler-Toledo DSC 821e 
instrument equipped with an intercooler (Mettler-Toledo, 
Switzerland). Indium and zinc standards were used to 
calibrate the DSC temperature and enthalpy scale. The 
samples were hermetically sealed in aluminium crucibles 
and heated at a constant rate of 10∘ C/min over a 
temperature range of 25–300∘C. Inert ambiance was 
continued by purging nitrogen gas at flow rate of 50 
mL/min9. 
Formulation of voriconazole microsponge 
The voriconazole microsponges were prepared by quasi 
emulsion solvent diffusion procedure with internal and 
external phases10. To prepare the internal phase, different 
concentrations of drug: polymer ratios were dissolved in 
ethyl acetate 20 ml. In this procedure, ethyl acetate was a 
proficient solvent for dissolving both the drug and the 
polymer. The external phase, which included the emulsifying 
agent dissolved in 80 ml of distilled water, was placed in the 
vessel, and stirred at 1000 rpm, and then the internal phase 
was slowly added into the stirring external phase. The 
mixture was then stirred at 1000 rpm for 8 h at room 
temperature to remove the ethyl acetate from the reaction 
flask. The formed microsponges were filtered through filter 
paper with a pore size of 0.45 µm, washed with distilled 
water and dried at room temperature for further use.
 
Table 1: Formula of voriconazole microsponges 
F.Code Drug 
(mg) 
Polymer 
(mg) 
Ethyl  
Acetate 
(ml) 
Triethyl 
citrate 
(ml) 
PVA  
(%w/v) 
Water 
(ml) 
VZM1 100 50 20 2 0.75 80 
VZM 2 100 100 20 2 0.75 80 
VZM 3 100 150 20 2 0.75 80 
VZM 4 100 200 20 2 0.75 80 
VZM 5 100 250 20 2 0.75 80 
VZM 6 100 300 20 2 0.75 80 
VZM 7 100 150 20 2 0.45 80 
VZM 8 100 150 20 2 0.6 80 
VZM 9 100 150 20 2 0.9 80 
VZM10 100 150 20 2 1 80 
 
Evaluation of voriconazole microsponges 
Production yield 
The production yield of voriconazole microsponges was 
determined by using formula mentioned below 11. 
                      
                            
                                  
         
(1) 
Drug content and Encapsulation efficiency 
Exactly weighed amount (100 mg) of microsponges 
containing drug was kept in 100 ml phosphate buffer 
solution (pH 7.4) for 12 h with constant stirring. Filtered 
samples (using 0.45 lm membrane filter) were analyzed at 
276 nm next to blank using UV spectrophotometer 
(Pharmaspec 1700, Shimadzu, Japan). Evaluation of drug 
content and encapsulation efficiency for all batches were 
completed using following expressions 
                 
    
   
                                 (2) 
                         
    
     
                    (3) 
Where Mact = actual Voriconazole content in weighed 
quantity of microsponges,                    
Mms = weighed quantity of microsponges and Mthe = 
theoretical Voriconazole content in microsponges 11.  
Scanning electron microscopy (SEM) 
For evaluating morphology and surface topography, the 
formulated microsponges were examined under scanning 
electron microscope (LEO 440i, UK) operating at 5 kV. Using 
double adhesive tape, samples were mounted on a metal 
stub and coating with platinum/palladium alloy under 
vacuum was done12.  
Particle size analysis 
Particle size analysis of prepared microsponges was carried 
out using particle size analyzer (Malvern Mastersizer Hydro 
2000, Malvern, UK). Microsponges were dispersed in double 
distilled water before running sample in instrument to 
ensure that light scattering signal (as indicated by particles 
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count per second) is within the sensitivity range of 
instrument13. 
Preparation of Voriconazole microsponge gel 
0.5 g of Carbopol 937 was taken and was uniformly 
dispersed in beakers containing sufficient quantity of water 
and was allowed to hydrate overnight. In another beaker, 
drug containing microsponge formulations was dispersed in 
propylene glycol and methanol. Ingredients like methyl 
paraben, sodium Meta bisulphite and disodium edetate were 
dissolved in water and added to the drug solvent system. 
Triethanolamine was added to adjust pH to 6.5–7.5. Gels 
prepared were degassed by ultra-sonication. Formulations 
of microsponges containing voriconazole were characterized 
for pH using pH meter, viscosity using a Brookfield digital 
viscometer (Viscometer VR 3000), spreadability and drug 
content14. Quantities of the ingredients were mentioned in 
Table 2.  
 
Table 2: Composition of Voriconazole microspongic gel formulation 
S.No Ingredients Quantity (%w/w) 
1 Drug Loaded Microsponges 1 
2 Propylene Glycol 40 
3 Methanol 8 
4 Methyl Paraben 0.15 
5 Sodium Meta Bisulphite 0.10 
6 Disodium Edetate 0.10 
7 Carbopol 934 1.00 
8 Triethanolamine Q.S 
9 Water 100 
 
 
Characterization of Voriconazole loaded microsponge 
gel 
The prepared voriconazole microsponge loaded gel was 
subject to different physical evaluations studies like; colour, 
pH, viscosity, spreadability15.  
In vitro release studies of Voriconazole loaded 
microsponge gel 
In vitro release studies were performed by artificial dialysis 
membrane. For this testing, a vertical Franz diffusion cell 
with a surface area of 2.54 cm2 and a reservoir capacity of 20 
ml was used. The artificial membrane was firmly positioned 
between the two halves of the diffusion cell. The receptor 
compartment contained phosphate buffer (pH 5.4), and its 
temperature maintained at 37 ± 0.50C and stirred constantly 
by magnetic stirrer. A predetermined amount of formulated 
gel (2.7 mg) containing 1 mg of voriconazole was placed on 
the donor side. A total of 2 ml of the sample was withdrawn 
from the receptor compartment at definite time intervals 
and replaced with an equal volume of fresh receptor fluid. 
The aliquots were correctly diluted with the receptor 
medium and analyzed by an UV spectrophotometer. 
Measurements were performed in triplicate and their means 
were reported16.  
 
Primary skin irritation studies 
Primary skin irritation studies of the voriconazole 
microspongic gel and plain gel were performed using nine 
male Wister rats. The experimental protocols for the animal 
study were approved by the Animal ethics committee of the 
department. (1358/ac/10/CPCSEA). Hair present on the 
back of each rat was removed using a depilatory and an area 
of 4 cm2 was marked. Nine rats were randomly assigned to 
three experimental groups of three rats each. Group I served 
as a control, group II was treated with voriconazole plain gel, 
group III was treated with Voriconazole microspongic gel. 10 
mg of sample were applied to each rat (2.5 kg-1 body mass) 
to groups I, II and III every day. The skin was cleaned before 
application of each dose and the reactions (erythema and 
edema), were scored after 1, 3, 5 and 7 days, as per the 
Draize patch test. The selection criteria for the Draize test 
and skin irritation score scale is shown in Table 3.  
The primary irritation index (PII) was calculated using 
following Equations. The results of triplicate measurements 
and their means were reported17.  
PII ¼ Average scores X variable factors 
Whereas average scores = Ʃ Erythema grade* + Ʃ Edema 
grade*/Number of animals*at 1, 3, 5 and 7 day and variable 
factor = types of skin X time of reading. 
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Table 3: Skin irritation score scale. 
Grading Description of irritant response 
0 No reaction 
+ Weakly positive reaction (usually characterized by mild 
erythema across most of the treatment site) 
++ Moderate positive reaction (usually distinct erythema, 
possibly spreading beyond the treatment site) 
+++ Strongly positive reaction (strong, often spreading erythema 
with edema) 
 
 
In vitro antifungal study of voriconazole loaded 
microspongic gel 
In vitro antifungal test was determined by Sabouraud 
dextrose agar disk diffusion method employing the ‘cup–
plate technique’ using sterilized Petri dish. Voriconazole 
plain gel (1 mg/ml), voriconazole microspongic gel (1 
mg/ml) and pure voriconazole as a standard  (1 mg/ml) 
prepared in DMSO and were placed into cups of size 8 mm, 
then into wells of a Sabouraud dextrose plate previously 
seeded with the test organism of Candida Albicans MTCC 
1637. After allowing diffusion of the solution for 2 h, the 
plates were incubated at 270C for 48 h. The zone of 
inhibition measured around each cup was compared with 
that of the standard. The results of triplicate measurements 
and their means were reported18. 
Ex vivo drug deposition study  
The ex vivo skin deposition study was carry out using tape 
stripping technique. On the day of the trial, rats were 
randomly assigned to three experimental groups of five rats 
each. Hair was removed from the back of each rat by using 
depilatory (Anne French) and an area of 2 cm2 was marked. 
Voriconazole plain gel (VLG) and voriconazole microsponge 
(VLMSG) formulations containing 1 mg equivalent of VL 
were applied on the skin and smoothly distributed on the 
marked area of different groups. At the end of 12 h, the skin 
surface of each group of animal was carefully washed with 
double distilled water and wiped with a cotton swab in 
order to take away excess formulation. The SC was removed 
by tape stripping with 15 pieces of adhesive tape. Tapes 
containing the SC were immersed in 5 ml methanol, vortex 
stirred for 2 min, filtered using a 0.45-µm membrane and 
analyzed for VL content by UV spectrophotometry. UV 
spectroscopy was selected as the method for determination 
as it is universal, cheap, rapid and easy to use and also has 
moderately high sensitivity. The amounts of drug detected in 
SC are indicative of drug deposition in the skin. 
Measurements were performed in triplicate and their means 
were reported19. 
In vivo antifungal activity of voriconazole loaded 
microspogic gel 
Wister rats, weighing 200g were used to compare the 
efficacy of developed-loaded microsponge formulations with 
that of plain gel using surgical wound model infected with 
Candida spp. The surgical wound model was adapted as 
previously described by McRipley and Whitney20,. Briefly; 
superficial surgical wounds were produced on the back of 
mice by making a longitudinal midline incision 2.3 ± 0.2 cm 
in length and extending down to the panniculus carnosus. A 
contaminated suture was inserted through the skin to infect 
the wound and secured by knotting and formulation was 
administered topically 0.1 ml/rat. Treatment was initiated at 
4 h after surgery and continued for further 3 days. On day 5 
after surgery, 16–20 h after the last topical application, the 
animals were killed by diethyl ether asphyxiation. A 1 x 2 cm 
area of skin, including the wound, was excised and 
homogenized in 1 ml of saline solution. The homogenates 
were serially diluted, plated on agar plates, and incubated at 
37°C. After 24 h, the number of colony forming units (CFU) 
per wound was counted. Bacterial counts were expressed in 
terms of mean ± SD.  
Accelerated stability studies 
The prepared voriconazole microspongic gel were packed in 
aluminium collapsible tubes (5 g) and subjected to stability 
studies at 50C, 250C/60 % RH, 300C/65 % RH, and 400C/ 75 
% RH for a period of 3 months. Samples were withdrawn at 
15-day time intervals and evaluated for physical appearance, 
pH, rheological properties, drug content, and drug release 
profiles21. 
RESULTS AND DISCUSSION 
In this experiment, voriconazole containing ethyl cellulose 
microsponges have been formulated and loaded into gel 
base which was check-up as topical carriers for the modified 
release for fungal infection. The impact of the drug: polymer 
ratio and emulsifier concentrations were studied on 
production yield, drug content, entrapment efficiency and 
mean particle size. The emulsion solvent diffusion method 
was opting to make microsponge because of its ease in 
manufacturing at large scale, cost effectiveness, reproducible 
and commercial purpose. To meet out the objective of this 
study we have chosen ethyl acetate as solvent because it has 
an ability to dissolve drug and polymer. 
Differential Scanning Calorimetric Analysis (DSC) 
DSC thermograms of pure drug and physical mixtures of 
drug and excipients are shown in Figure 1. The pure drug, 
voriconazole showed an endothermic peak at 130.030C and 
the physical mixture of drug and excipients showed 
endothermic peaks at 129.030C respectively. In this case, 
melting endotherm of drug was well protected with minor 
changes in terms of shifting in the temperature of the melt. It 
is recognized that the quantity of material used, particularly 
in drug-excipient mixtures, could influence the peak 
enthalpy. Thus, this slight change in the melting endotherm 
of drug could be due to the combination of drug and 
excipient, which lowered the purity of the constituent in the 
mixture, and this, might not necessarily point out potential 
incompatibility22.
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   Figure 1: DSC thermograms of (A) Pure voriconazole and (B) Physical mixture of voriconazole PVA and EC 
 
Production yield, drug content and encapsulation 
efficiency 
The results of production yield, drug content and 
encapsulation efficiency of microsponges were described in 
Table 4 Production yield of voriconazole was significantly 
impacted by drug: polymer proportion and concentration of 
the surfactant. Increase in the drug: polymer ratio resulted 
into increased production yield. When drug: polymer ratio 
was 1:1 (VZM1) the production yield was very low, i.e. 
20.18% while for drug: polymer ratio 1:3 (VZM6) it was 
78.12%. Besides this drug polymer ratio, surfactant 
concentration also has impact on production yield when the 
surfactant concentration was 0.75% w/v the production 
yield was increased (VZM1-VZM6). As the concentration of 
surfactant reduced from 0.75% to 0.45% (VZM7-VZM8) 
yield was noticeably reduced to 26.28% and 36.11%.  The 
production yield was drastically reduced from the 
formulations VZM9-VZM10 due to high concentration of 
surfactant (0.9%-1%) the reason for the less production 
yield may be due to the development of unreasonable foam 
and evaporation of the drugs while preparing microsponges. 
The drug loading efficiency did not reach 100% at all ratios 
of drug: polymer used. This could be due to dissolution of 
drug in the solvent or in the aqueous phase. The outcome of 
encapsulation efficiency shows that, the higher drug loading 
efficiency was attaining at lower drug: polymer ratios. 
Additionally surfactant concentration also a vital part in 
encapsulation efficiency, utilization of higher amount of 
surfactant in the formulations of VZM9 and VZM10 caused 
great drug payloads and it influences the production yield. 
The entrapment efficiency of voriconazole microsponges 
was noted in the range of 58.10% to 92.10% individually. 
Based on the above results we considered VZM3 as 
optimized formulation and it was evaluated.  
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Table 4:  Production yield, drug content and encapsulation efficiency of voriconazole microsponges. 
F.Code    Production yield (%)   Drug content (%) EE (%) 
VZM1 20.18±0.11 46.07 ± 0.21 92.10±0.01 
VZM2 35.48±0.21 29.00 ± 0.23 87.22±0.03 
VZM3 50.15±0.28 21.22 ± 0.17 83.20±0.07 
VZM4 62.11±0.02 19.05 ± 0.05 79.24±0.04 
VZM5 69.08±0.05 16.25 ± 0.08 76.16±0.01 
VZM6 78.12±0.01 14.05 ± 0.05 69.12±0.06 
VZM7 26.28±0.01 12.15 ± 0.17 58.10±0.02 
VZM8 36.11±0.12 10.10 ± 0.11 66.30±0.03 
VZM9 19.40±0.11 10.00 ± 0.12 70.31±0.01 
VZM10 18.54±0.19 9.13 ± 0.19 71.15±0.04 
 
Scanning electron microscopy (SEM) 
SEM images of voriconazole-loaded microsponges as shown 
in Figure 2. It shows that the microsponges were uniform, 
spherical in shape, and porous. No drug crystals were 
observed visually. The pores were created may be due to by 
diffusion of solvent ethyl acetate from surface of 
microsponges.
 
 
 
          Figure 2: Scanning electron microscopy (SEM) 
 
Particle size analysis 
Using the laser light-scattering technique, a particle size 
distribution map by volume of the voriconazole microsponge 
was determined, which illustrate that the specific area, 
surface diameter and diameter by volume of the particles 
were 0.123 m2/g, 48.68 μm and 70.08 µm, respectively. The 
particle size distribution of (0.1), d (0.5), d (0.9) and d (1) 
were 29.25 μm, 65.06 μm, 119.47 μm and 177.23 μm and the 
particle uniformity was 0.569. Figure 3. 
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Figure 3: Particle size Characterization of Drug loaded microsponge 
 
Characterization of voriconazole loaded microsponge 
gel 
In vitro release studies of voriconazole loaded 
microsponge gel 
The impact of the composition and vehicle in the 
formulation was investigated using an artificial cellophane 
membrane with phosphate buffer (pH 5.4). Being a topical 
preparation, the release medium was adjusted to the pH of 
the skin (i.e., pH 5.4). The in vitro release profiles of 
voriconazole from microsponge (VZMG3) and plain 
voriconazole gel (SVG) are shown in Figure 4.  The obtained 
results indicated that voriconazole plain gel released 94.15% 
of drug within 2 hrs, whereas voriconazole loaded 
microsponges extended the drug release up to 24 hrs with 
93.79%.
 
 
 
Figure 4: In vitro release studies of voriconazole plain gel and voriconazole microsponge gel 
 
Evaluation of voriconazole microspongic gels 
The prepared voriconazole loaded microsponge gels were 
inspected visually for their color, texture and appearance. All 
formulations were transparent, viscous and good 
homogeneity without lumps. The pH values of all prepared 
formulations were found in the range of 6.5–7.1, which is 
supposed to be suitable to pass up the threat of nuisance on 
application to the skin. The microsponge loaded carbopol gel 
was thicker than the gel loaded with plain drug. The 
viscosities of VZMGs were observed to be 24,210 to 46,730 
cPs. The spreadability was observed to be in the range of 
6.30 to 11.31g cm/s which is demonstrating that 
spreadability of k microsponge gel was great. The results 
were depicted on Table 5.  
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Table 5: Evaluation of voriconazole microsponge loaded carbopol gel. 
 
 
Skin irritation studies 
The overall scores for erythema and edema of the rats at the 
1st, 3rd, 5th and 7th days were performed. The PII was 
calculated based on the sum of the scored reactions divided 
by 48 (four scoring intervals multiplied by two test 
parameters multiplied by three rats). Voriconazole 
microsponge did not produce erythema and was a non-
irritant (PII: 0.00), whereas voriconazole plain gel exhibited 
some erythema and a PII of 0.04 and 0.06, indicating scarcely 
noticeable irritation on to the rat skin Figure 5. 
 
 
Figure 5:  Skin irritation study (a) Control (b) Plain Fluconazole gel  
(c) Placebo (d) Voriconazole loaded microspongic gel 
 
In vitro antifungal study of voriconazole loaded 
microspongic gel 
The remarkable differences in antifungal activity were 
observed between VLMSG, VLG and control formulations 
(DMSO). VLMSG produced 1.9±0.07 mm of zone of inhibition 
but there were no zone of inhibition was seen with disk 
containing DMSO and plain gels against Candida Albicans. 
Figure.6
 
F.Code Visual inspection pH Spreadability Viscosity 
VZMG1 Transparent 6.9±0.01 6.30±0.04 24,210±0.79 
VZMG2 Transparent 6.6±0.01 8.40±0.38 28,630±1.26 
VZMG3 Transparent 6.8±0.03 11.31±0.31 33,520±1.64 
VZMG4 Transparent 6.5±0.01 10.09±0.43 39,540±1.65 
VZMG5 Transparent 6.8±0.02 10.07±0.59 42,630±1.15 
VZMG6 Transparent 7.2±0.04 7.70±0.58 46,730±1.20 
VZMG7 Transparent 7.0±0.01 11.24±0.39 35,710±1.15 
VZMG8 Transparent 7.1±0.01 11.20±0.04 35,260±1.08 
VZMG9 Transparent 6.3±0.02 10.08±0.29 35,580±1.12 
VZMG10 Transparent 6.2±0.03 10.21±0.34 35,450±1.14 
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Figure 6:  In vitro antifungal studies (A) Plain gel (B) 
Voriconazole microsponge gel (C) Control 
Ex vivo drug deposition study  
For successful topical medication treatment requires 
adequate quantity of medication taken-up by skin over a 
specific timeframe for maximal therapeutic activity. The drug 
extraction efficiency showed that 228.68 µg and 57.45µg of 
voriconazole by tape stripping method, from which their 
depositions were calculated. The amount of VL deposited in 
the skin (sc) from VLMSGS was 126.48±3.24g/cm2 which 
was 3fold greater than that of VLG 40.8±3.11g/cm2 at the 
end of 24h. This demonstrated that the microsponges 
enhanced the drug residence period on skin. Figure.7 
 
Figure 7:  In vivo drug deposition of VZM & VZMG 
 
In vivo antifungal activity of voriconazole loaded 
microspogic gel 
VLMG gel (once daily); VLG gel (three times a day) 
administered topically compared with untreated control 
groups. During the treatment period the bacterial counts 
were observed, VLMG gel formulation significantly reduced 
the mean bacterial counts 3.18 ± 0.22 as compared with VLG 
2.51±0.13 log10 CFU/wound Figure. 8. At the same time, 
there was no difference has been observed in untreated 
group. Therefore, the results proved that microsponge 
formulations extensively different from normal gel 
preparations. 
 
Figure 8: Wound healing property of VZMG against 
Candida spp. mean ± SD (n = 3) 
 
Accelerated stability studies 
The developed VZ-loaded microsponge formulation was 
found to be stable upon storage for 3 months. No major 
changes were noticed in their physical properties and drug 
release profiles. 
SUMMARY CONCLUSION 
Voriconazole microsponge was formulated using the quasi 
emulsion solvent diffusion method and characterized as an 
effective carrier for the topical delivery of the drug. The 
properties of the developed system were greatly influenced 
by the drug: polymer ratio. The prepared microsponge gel 
formulation confirmed controlled release of the drug. The 
primary skin irritation tests exposed that microsponge gel 
formulation was non-irritant. In addition, voriconazole 
engaged antifungal activity on encapsulation in 
microsponges. The microsponges confirmed to be a potential 
carrier for voriconazole in topical fungal treatment. The 
formulations showed excellent maintenance of drug on to the 
skin, which representing microsponge gel is a good drug 
delivery system as compared with plain gel. The 
microsponge-based gel formulations will have significantly 
advanced part in treatment of primary and secondary fungal 
skin infections. 
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